(Q37950515)

25 August 2017

title

Recent developments in treatment stratification for metastatic breast cancer (English)

1 reference

25 August 2017

main subject

metastatic breast cancer

1 reference

Charles Swanton

2

0 references

author name string

Sarah Barton

series ordinal

1

1 reference

25 August 2017

publication date

1 November 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

71

1 reference

25 August 2017

issue

16

1 reference

25 August 2017

page(s)

2099-2113

1 reference

https://scigraph.springernature.com/pub.10.2165/11594480-000000000-00000

25 August 2017

exact match

0 references

cites work

International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Does more intense palliative treatment improve overall survival in metastatic breast cancer patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

The influence of chemotherapy on survival after recurrence in breast cancer--a population-based study of patients treated in the 1950s, 1960s and 1970s

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

A systematic review of taxane-containing regimens for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Histamine release in dogs by Cremophor El® and its derivatives: Oxethylated oleic acid is the most effective constituent

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Weekly paclitaxel in the adjuvant treatment of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Triple-negative breast cancer: clinical features and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Triple-Negative Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Basal-like breast cancer and the BRCA1 phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

BRCA1 dysfunction in sporadic basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Targeting the DNA repair defect of BRCA tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Resistance to therapy caused by intragenic deletion in BRCA2

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Basal-like breast cancer: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Breast cancer genome heterogeneity: a challenge to personalised medicine?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active th

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11594480-000000000-00000

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

21 January 2018

1 reference

12 December 2020

Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme

1 reference

12 December 2020

Hypersensitivity reactions from taxol

1 reference

12 December 2020

Phase II Trial of Ixabepilone, an Epothilone B Analog, in Patients With Metastatic Breast Cancer Previously Untreated With Taxanes

1 reference

12 December 2020

Bisphosphonates for breast cancer

1 reference

12 December 2020

Distant recurrence in breast cancer. Survival expectations and first choice of chemotherapy regimen

1 reference

12 December 2020

1 reference

12 December 2020

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition

1 reference

12 December 2020

Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer

1 reference

12 December 2020

Nanoparticle albumin-bound paclitaxel for metastatic breast cancer

1 reference

12 December 2020

Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.

1 reference

12 December 2020

Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura.

1 reference

12 December 2020

Taxane containing regimens for metastatic breast cancer

1 reference

12 December 2020

Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women

1 reference

12 December 2020

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

12 December 2020

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM

1 reference

12 December 2020

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.

1 reference

12 December 2020

Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer

1 reference

12 December 2020

Improved survival of patients with metastatic breast cancer receiving combination chemotherapy

1 reference

12 December 2020

RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br

1 reference

12 December 2020

10.2165/11594480-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

25 August 2017

1047944529

0 references

1 reference